Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciprofloxacin vs TMP-SMX for Severe COPD Exacerbation
NCT00791505Phase 3Completed
- Sponsor
- Université de Monastir
- Start
- Jul 2002
- Primary completion
- Jun 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ciprofloxacin in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Université de Monastir. Primary endpoints: Mortality (in ICU and in the hospital) at 30 days and Rate of additional antibiotherapy course at 30 days. Started Jul 2002; status: completed.
02
Drugs
ciprofloxacin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00791505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00791505.